Prognosis Of Prostate Cancer

prognosis of prostate cancer

An analysis of data on 945 patients with prostate cancer that is managed with active surveillance shows differences in outcomes depending on whether the patient was low or intermediate risk at diagnosis. Compared to patients with low-risk disease, those MONDAY, Feb. 23, 2015 (HealthDay News) -- Choosing active surveillance over treatment for prostate cancer may decrease the odds of survival in men with intermediate-risk cancer, a new study says. The risk of death over 15 years for men with intermediate information about any family history of prostate cancer, the results of the palpation, and the volume of the prostate increase the precision of the ProstateCheck prognosis. Based on the user's information, the app uses specially developed algorithms to At present, the main end point for clinical trials in metastatic castration-resistant prostate cancer (mCRPC) is overall survival, but the availability of multiple life-prolonging therapies for this indication makes overall survival a formidable hurdle in "A significant Phase II survival benefit suggests Prostvac immunotherapy has the potential to revolutionize prostate cancer treatment," analysts at Jefferies said in a note. Last week Bavarian said according to results of a small early-stage trial (HealthDay News) — Choosing active surveillance over treatment for prostate cancer may decrease the odds of survival in men with intermediate-risk cancer, according to research scheduled to be presented at the American Society of Clinical Oncology's .

Prostate cancer is the most common malignancy in men of all ages whereas others may prioritise local treatment and potentially improved survival," she told Reuters Health by email. This is particularly pressing because this population constitutes the fastest growing subpopulation of cancer patients in the United States." Dr. Zheng and colleagues also found that blacks had poorer survival than whites for all cancers except prostate Low nadir serum testosterone in the first year of androgen deprivation therapy was associated with improved survival and time to progression in men with recurrent prostate cancer, reported Dr. Laurence Klotz and his coauthors at the University of Toronto ConfirmMDx for Prostate Cancer is an epigenetic test that was developed technology and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. For more information visit .

prognosis of prostate cancer Prostate Cancer Hormone Treatment | eHow 198 x 98 · 5 kB · jpeg
prognosis of prostate cancer TITLE_IMG2 IMG_RES2
prognosis of prostate cancer TITLE_IMG3 IMG_RES3
prognosis of prostate cancer TITLE_IMG4 IMG_RES4
prognosis of prostate cancer TITLE_IMG5 IMG_RES5
prognosis of prostate cancer TITLE_IMG6 IMG_RES6
prognosis of prostate cancer TITLE_IMG7 IMG_RES7
prognosis of prostate cancer TITLE_IMG8 IMG_RES8
prognosis of prostate cancer TITLE_IMG9 IMG_RES9
prognosis of prostate cancer TITLE_IMG10 IMG_RES10